Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 3, 2003, Pages 386-390

  Kita, Tomoko ^a   Sakaeda, Toshiyuki ^a   Baba, Takahiko ^c   Aoyama, Nobuo ^a   Kakumoto, Mikio ^a   Kurimoto, Yoshie ^a   Kawahara, Yuko ^a   Okamura, Noboru ^c   Kirita, Shirou ^c   Kasug, Masato ^b   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

Anti human CYP antibody; Human liver microsome; Lansoprazole, rabeprazole; Omeprazole; P450 activity

Indexed keywords

CYTOCHROME P450 2C19; IS 735; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIBODY; BENZIMIDAZOLE DERIVATIVE; CYP2C19 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; ENZYME INHIBITOR; MIXED FUNCTION OXIDASE; PROTON PUMP; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG METABOLISM; DRUG POTENTIATION; GENOTYPE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; VALIDATION PROCESS; ADULT; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; INSTRUMENTATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANALYSIS OF VARIANCE; ANTIBODIES; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON PUMPS; PROTON-TRANSLOCATING ATPASES;

EID: 0642379417     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.386     Document Type: Article

References (15)

1. Sakai T., Aoyama N , Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., Hohda T., Sirasaka D , Tamura T., Tanigawara Y., Kasuga M., Okumura K., Pharm Res., 18, 721-727 (2001).
2. Tanigawara Y., Aoyama N., Kita T., Shirakawa K., Komada F., Kasuga M., Okumura K., Clin. Pharmacol. Ther., 66, 528-534 (1999).
3. Aoyama N., Tanigawara Y., Kita T., Sakai T , Shirakawa K., Shirasaka D., Komada F., Okumura K., Kasuga M., J Gastroenterol , 34, 80-83 (1999).
4. Kita T., Tanigawara Y., Aoyama N., Hohda T., Saijoh Y., Komada F., Sakaeda T., Okumura K . Sakai T , Kasuga M., Pharm. Res, 18, 615-621 (2001).
5. Kita T., Sakaeda T., Aoyama N , Sakai T., Kawahara Y., Kasuga M., Okumura K., Biol. Pharm Bull., 25, 923-927 (2002).
6. Chiba K., Kobayashi K., Manabe K., Tani M., Kamataki T., Ishizaki T., J. Pharmacol Exp. Ther., 266, 52-59 (1993).
7. Andersson T., Miners J. O., Veronese M. E., Birkett D. J., Br. J. Clin. Pharmacol , 37, 597-604 (1994).
8. Pichard L., Curi-pedrosa R., Bonfils C., Jacqz-aigrain E., Domergue J., Joyeux H., J. Pharmcol Exp. Ther., 47, 410-418 (1995).
9. Vanderbranden M., Ring B. J., Binkley S. N., Wrighton S. A., Pharmacogenetics, 6, 81-91 (1996).
10. Karam W. G., Goldstein J. A., Lasker J. M., Ghanayem B. I., Drug Metab. Dispos., 24, 1081-1087 (1996).
11. Kaminsky S., Fasco M. J., Guengerich F. P , Methods Enzymol., 74, 262-272 (1981).
12. Yamazaki H., Inoue K., Shaw P. M., Checovich W. J., Guengerich F. P., Shimada T., J. Pharmacol. Exp Ther., 283, 434-442 (1997).
13. Shu Y., Wang L. S., Xu Z. H., He N., Xiao W. M., Wang W., Huang S. L., Zhou H. H., J. Pharmacol. Exp. Ther., 295, 844-851 (2000).
14. Abelo A., Andersson T. B., Antonsson M., Naudot A. K., Skanberg I., Weidolf L., Drug Metab. Dispos., 28, 965-972 (2000).
15. Katsuki H., Hamada A., Nakamura C., Arimori K., Nakano M., Eur. J. Clin. Pharmacol., 57, 709-715 (2001).